Swedish Orphan Biovitrum and Pharming sign Rhucin distribution agreement
Swedish Orphan Biovitrum and Pharming Group NV announced an exclusive 10 year distribution agreement, under which Swedish Orphan Biovitrum will distribute Rhucin® in 24 EU countries, Norway, Iceland and Switzerland.
Under the agreement, Swedish Orphan Biovitrum will pay to Pharming an undisclosed upfront payment and a regulatory approval milestone. In addition, Swedish Orphan Biovitrum will pay a supply price that will include tiered performance based royalties to Pharming. Swedish Orphan Biovitrum will also have the right to participate in the future development and distribution of Rhucin® in the agreed countries for additional indications.
Rhucin® is a recombinant human C1 inhibitor for the acute treatment of Hereditary Angioedema (HAE) attacks. Pharming submitted an MAA for Rhucin® to the European Medicines Agency (EMA) in September 2009.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Diabetes advance: Researchers find gene that causes resistance to insulin - Discovery is first gene known to affect how insulin works, not how it is produced

ZEISS Ventures invests in life science start-up InSphero to drive 3D cell culture research - Strategic investment is closely linked to ZEISS Research Microscopy Solutions and its capabilities in automated, high-resolution imaging and 3D image analysis

Culture Biosciences Raises $80M Series B to Tackle Demand for Large-Scale Biomanufacturing - Culture is closing the gap in manufacturing capacity with its large-scale cloud bioreactors
Mechanical heart valve prosthesis superior to biological
